- Home
- TLSI vs JYNT Comparison
TLSI vs JYNT Comparison
Compare TLSI & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- JYNT
- Stock Information
- Founded
- TLSI 2010
- JYNT 2010
- Country
- TLSI United States
- JYNT United States
- Employees
- TLSI N/A
- JYNT N/A
- Industry
- TLSI Medical Specialities
- JYNT Multi-Sector Companies
- Sector
- TLSI Health Care
- JYNT Miscellaneous
- Exchange
- TLSI Nasdaq
- JYNT Nasdaq
- Market Cap
- TLSI 150.0M
- JYNT 170.3M
- IPO Year
- TLSI N/A
- JYNT 2014
- Fundamental
- Price
- TLSI $4.80
- JYNT $10.02
- Analyst Decision
- TLSI Strong Buy
- JYNT Strong Buy
- Analyst Count
- TLSI 5
- JYNT 3
- Target Price
- TLSI $10.90
- JYNT $16.33
- AVG Volume (30 Days)
- TLSI 95.6K
- JYNT 82.6K
- Earning Date
- TLSI 11-13-2025
- JYNT 11-06-2025
- Dividend Yield
- TLSI N/A
- JYNT N/A
- EPS Growth
- TLSI N/A
- JYNT N/A
- EPS
- TLSI N/A
- JYNT N/A
- Revenue
- TLSI $35,990,000.00
- JYNT $53,449,713.00
- Revenue This Year
- TLSI $56.79
- JYNT $8.06
- Revenue Next Year
- TLSI $54.15
- JYNT $11.18
- P/E Ratio
- TLSI N/A
- JYNT N/A
- Revenue Growth
- TLSI 45.50
- JYNT 277.36
- 52 Week Low
- TLSI $3.42
- JYNT $9.58
- 52 Week High
- TLSI $5.88
- JYNT $13.47
- Technical
- Relative Strength Index (RSI)
- TLSI 51.02
- JYNT 32.25
- Support Level
- TLSI $4.41
- JYNT $9.85
- Resistance Level
- TLSI $4.93
- JYNT $10.74
- Average True Range (ATR)
- TLSI 0.28
- JYNT 0.20
- MACD
- TLSI -0.05
- JYNT -0.05
- Stochastic Oscillator
- TLSI 42.25
- JYNT 18.68
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.